Akt inhibitors in clinical development for the treatment of cancer

SK Pal, K Reckamp, H Yu, RA Figlin - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: The evolution of targeted therapies is dependent upon identification
of cellular moieties that can be pharmacologically modulated. As one such example, the …
被引用次数：274 相关文章

Akt inhibitors in clinical development for the treatment of cancer

SK Pal, K Reckamp, H Yu… - Expert opinion on …, 2010 - pubmed.ncbi.nlm.nih.gov
Importance of the field The evolution of targeted therapies is dependent upon identification
of cellular moieties that can be pharmacologically modulated. As one such example, the …

[引用][C] Akt inhibitors in clinical development for the treatment of cancer

SK Pal, K Reckamp, H Yu, RA Figlin - Expert Opinion on Investigational …, 2010 - cir.nii.ac.jp
Akt inhibitors in clinical development for the treatment of cancer | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 論文·デ恁郡颏丹す …
[HTML] nih.gov

[HTML][HTML] Akt inhibitors in clinical development for the treatment of cancer

SK Pal, K Reckamp, H Yu, RA Figlin - Expert opinion on …, 2010 - ncbi.nlm.nih.gov
Importance of the field—The evolution of targeted therapies is dependent upon identification
of cellular moieties that can be pharmacologically modulated. As one such example, the …

Akt inhibitors in clinical development for the treatment of cancer.

SK Pal, K Reckamp, H Yu, RA Figlin - Expert Opinion on …, 2010 - europepmc.org
Importance of the field—The evolution of targeted therapies is dependent upon identification
of cellular moieties that can be pharmacologically modulated. As one such example, the …